Comparative Pharmacology
Head-to-head clinical analysis: ALPROSTADIL versus TRYVIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPROSTADIL versus TRYVIO.
ALPROSTADIL vs TRYVIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alprostadil is a synthetic prostaglandin E1 (PGE1) that causes vasodilation by binding to prostanoid EP receptors, increasing intracellular cAMP, and relaxing smooth muscle. It also inhibits platelet aggregation.
Tryvio (vobadimustat) is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stabilizes HIF-α, leading to increased erythropoietin production and stimulation of erythropoiesis.
Initial: 20-40 mcg IV bolus over 1-2 seconds; then 30-70 mcg/min continuous IV infusion for erectile dysfunction via intracavernosal injection: 2.5-10 mcg; for patent ductus arteriosus: 0.05-0.1 mcg/kg/min continuous IV infusion.
Adults: 0.25 mg subcutaneously once daily.
None Documented
None Documented
Clinical Note
moderateAlprostadil + Limaprost
"Alprostadil may increase the antiplatelet activities of Limaprost."
Clinical Note
moderateAlprostadil + Epoprostenol
"Alprostadil may increase the antiplatelet activities of Epoprostenol."
Clinical Note
moderateTiaprofenic acid + Alprostadil
"The therapeutic efficacy of Alprostadil can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Alprostadil
5-10 minutes; rapidly metabolized in the lungs, clinical effect lasts longer due to continuous infusion.
Terminal elimination half-life 44-60 hours in healthy adults; prolonged in hepatic impairment (up to 120 hours).
Primarily via urine (90%) as metabolites; 10% unchanged; minimal fecal excretion.
Primarily hepatic metabolism; 90% as inactive metabolites in feces, <5% unchanged in urine; <5% in bile.
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog
"The therapeutic efficacy of Alprostadil can be decreased when used in combination with Carprofen."